Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1-Positive mRCC
This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: David F. McDermott, MD Tags: Videos Genitourinary Cancers Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Study